Tevogen Inc. — Form 8-K
Filed August 26, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 58/100
What the filing says
Tevogen Inc. adopted two corporate amendments effective August 24-25, 2026: (1) amended its Certificate of Incorporation to permit stockholder action by written consent, and (2) increased its 2024 Omnibus Incentive Plan share reserve by 100,000,000 shares to a new total of 102,800,000 shares, plus an annual 5% increase (or lesser amount determined by Board) starting in 2025 for up to 10 years. No financial transactions, counterparties, or dollar amounts specified.
Why this rating
Share pool increase of 100M is ~157% of current market cap; material dilution risk. Written consent amendment is routine governance. Significance moderate—dilution concern offsets by lack of immediate cash impact or business disruption.
See more from August 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.